MedTrace Logo

Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions

NCT02059915 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2016-04-04

No results posted yet for this study

Summary

To Compare The Bioavailability Of 40 Mg Doses Of Pf-00345439 Modified Formulation K Vs. Original Formulation X Under Fed And Fasting Conditions In Healthy Volunteers

Conditions

  • Healthy

Interventions

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation X, single dose, under fed conditions

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions

DRUG

Oxycodone

One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions

Sponsors & Collaborators

  • Pain Therapeutics

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02059915 on ClinicalTrials.gov